Dr. Mohamad H. Badawi
Claim this profileWest Virginia University Charleston Division
Studies Cancer
Studies Tumors
17 reported clinical trials
54 drugs studied
About Mohamad H. Badawi
Education:
- Graduated with an MD from Damascus University Faculty of Medicine, Syria, in 2006.
- Completed a Residency in Internal Medicine at West Virginia University Charleston Division in 2015.
- Finished a Fellowship in Pulmonary and Critical Care Medicine at West Virginia University Charleston Division in 2018.
Experience:
- Currently serves as an Assistant Professor of Medicine at West Virginia University Charleston Division, specializing in Pulmonary and Critical Care Medicine.
Area of expertise
1Cancer
Stage I
Stage IV
Stage II
2Tumors
Stage I
Stage II
Stage IV
Affiliated Hospitals
Clinical Trials Mohamad H. Badawi is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
More about Mohamad H. Badawi
Clinical Trial Related4 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Mohamad H. Badawi has experience with
- Cyclophosphamide
- Etoposide
- Doxorubicin Hydrochloride
- Carboplatin
- Cytarabine
- Dactinomycin
Breakdown of trials Mohamad H. Badawi has run
Cancer
Tumors
Leukemia
Rhabdomyosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mohamad H. Badawi specialize in?
Mohamad H. Badawi focuses on Cancer and Tumors. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Mohamad H. Badawi currently recruiting for clinical trials?
Yes, Mohamad H. Badawi is currently recruiting for 5 clinical trials in Charleston West Virginia. If you're interested in participating, you should apply.
Are there any treatments that Mohamad H. Badawi has studied deeply?
Yes, Mohamad H. Badawi has studied treatments such as Cyclophosphamide, Etoposide, Doxorubicin Hydrochloride.
What is the best way to schedule an appointment with Mohamad H. Badawi?
Apply for one of the trials that Mohamad H. Badawi is conducting.
What is the office address of Mohamad H. Badawi?
The office of Mohamad H. Badawi is located at: West Virginia University Charleston Division, Charleston, West Virginia 25304 United States. This is the address for their practice at the West Virginia University Charleston Division.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.